T-Cell Depleted Double UCB for Refractory AML

NCT01464359 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

3

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Acute Myelogenous Leukemia
Refractory Acute Myelogenous Leukemia

Interventions

DRUG: Allopurinol
DRUG: Fludarabine
RADIATION: Total body irradiation
DRUG: Cyclophosphamide
DRUG: Levetiracetam
DRUG: Busulfan
BIOLOGICAL: Umbilical Cord Blood Transplantation
BIOLOGICAL: Interleukin-2

Sponsor

Masonic Cancer Center, University of Minnesota